Book an Appointment

Cybersecurity for Medical Devices

Which cybersecurity requirements the MDR imposes on manufacturers – and how MDCG 2019-16, IEC 81001-5-1 and the AI Act set the framework for the entire product life cycle.

Connected medical devices are both an attack surface and a patient safety risk: an exploited vulnerability can directly impair a device’s clinical function. Regulation (EU) 2017/745 (MDR) therefore anchors information security as a general safety and performance requirement in Annex I – further specified by the MDCG 2019-16 guidance and the life cycle standard IEC 81001-5-1. The horizontal Cyber Resilience Act explicitly does not apply to MDR products; the cybersecurity obligations derive entirely from medical device law. For AI-based medical devices, the AI Act has been in place since 2024 as a second regulatory framework.

The Essentials at a Glance

01

MDR Annex I: The general cybersecurity requirements

The MDR does not use the term “cybersecurity” literally, but Annex I sets out clear requirements: Section 17.1 requires, for devices incorporating programmable electronic systems, repeatability, reliability and performance in line with their intended purpose; Section 17.2 requires software to be developed in accordance with the state of the art, taking into account the life cycle, risk management – including information security – as well as verification and validation. Under Section 17.4, manufacturers must set out minimum requirements concerning hardware, IT network characteristics and IT security measures, including protection against unauthorised access; Section 18.8 and Section 23.4(ab) add protection against unauthorised access and the obligation to communicate these minimum requirements in the instructions for use. The Cyber Resilience Act (Regulation (EU) 2024/2847) explicitly excludes medical devices from its scope in Art. 2, because the MDR already imposes IT security requirements covering the entire life cycle.

02

MDCG 2019-16: The central cybersecurity guidance

The guidance MDCG 2019-16 Rev. 1 (July 2020) issued by the Medical Device Coordination Group specifies how the Annex I requirements are to be implemented across the entire life cycle: secure by design, a dedicated security risk management process interlinked with safety risk management, and a catalogue of security capabilities such as authentication, authorisation, encryption and audit logging. It establishes the principle of joint responsibility: alongside the manufacturer, integrators, operators and users also bear defined obligations for secure operation – such as secure configuration and compliance with the manufacturer’s minimum IT requirements. A mapping table cross-references the relevant sections of MDR and IVDR Annex I, and an annex with case examples distinguishes cybersecurity incidents from reportable serious incidents.

03

IEC 81001-5-1: The secure life cycle for health software

IEC 81001-5-1:2021 (“Health software and health IT systems safety, effectiveness and security – Part 5-1: Security – Activities in the product life cycle”) defines the process requirements for the secure development and maintenance of health software: security risk management with threat modelling, security testing, configuration management, and processes for vulnerability monitoring and problem resolution. It extends the life cycle structure of IEC 62304 with security activities and is modelled on IEC 62443-4-1. The European version EN IEC 81001-5-1:2022 is earmarked for harmonisation under the MDR and IVDR, but even after the update of the lists of standards in June 2026 (Commission Implementing Decision (EU) 2026/1231) it has still not been cited in the Official Journal of the EU – so there is no presumption of conformity. In practice, notified bodies nevertheless treat the standard as the state of the art for demonstrating compliance with the requirements of Annex I Sections 17.2 and 17.4.

04

AI-based medical devices: Interplay between the MDR and the AI Act

The AI Act (Regulation (EU) 2024/1689, in force since 1 August 2024) complements the MDR but does not replace it: under Art. 6(1), an AI system qualifies as high-risk AI if it is a safety component of a medical device, or is itself such a device, and its conformity assessment requires a notified body – which, under the MDR, is regularly the case from class IIa upwards. The FAQ MDCG 2025-6 (June 2025), developed jointly with the AI Board, answers 36 practical questions on the interplay between the two frameworks, for example on role mapping (manufacturer under the MDR corresponds to provider under the AI Act) and on combining the conformity assessments. On timelines, 2026 brought a significant change: the “Digital Omnibus” agreed by Parliament and Council in May 2026 postpones the application of the high-risk obligations for AI systems embedded in regulated products from 2 August 2027 to 2 August 2028; this takes effect upon publication in the Official Journal of the EU. A more far-reaching proposal to largely exempt medical devices from the AI Act was not adopted.

05

Post-market surveillance and vulnerability handling

Because the threat landscape and vulnerabilities keep changing after a device has been placed on the market, the MDR requires an active post-market surveillance system (Art. 83) with a PMS plan (Art. 84) and – depending on the class – a PMS report or a periodic safety update report (PSUR, Art. 86); under MDCG 2019-16, cybersecurity is explicitly part of this system. If an exploited or exploitable vulnerability leads to a serious incident, the vigilance obligations under Art. 87 apply: reporting no later than 15 days after awareness, 10 days in the event of death or an unanticipated serious deterioration in health, and 2 days in the event of a serious public health threat; trend reporting under Art. 88 comes on top. IMDRF codes are available for reporting security-related causes, such as “Computer System Security Problem” and “Software Security Vulnerability”. From a regulatory perspective, security patches are corrective actions and may be reportable as field safety corrective actions (FSCA) – a structured vulnerability handling process in line with IEC 81001-5-1 connects both worlds. Worth watching: the Commission proposal for the MDR revision presented in December 2025 (COM(2025) 1023) additionally provides for CRA-style reporting of actively exploited vulnerabilities to CSIRTs and ENISA – not yet adopted.

06

Notified bodies: Expectations for cybersecurity evidence

Notified bodies assess cybersecurity as part of the technical documentation under MDR Annexes II and III – from the security risk analysis and the definition of security capabilities to evidence from security testing and the processes for vulnerability handling and PMS. The Team-NB position paper “Cyber Security” (October 2022) describes the common expectations of the European notified bodies regarding this evidence; in a letter of February 2026, Team-NB also urges the swift harmonisation of standards such as IEC 81001-5-1. As long as harmonised cybersecurity standards are lacking, there is no presumption of conformity – manufacturers must substantiate the state of the art themselves and should build their line of argument along MDCG 2019-16 and IEC 81001-5-1.

Standards & Sources

The content on this page is based on the following publicly available guides and studies.

Amtsblatt der EU / EUR-Lex · 2017

Verordnung (EU) 2017/745 über Medizinprodukte (MDR)

Annex I Sections 17.1, 17.2, 17.4, 18.8 and 23.4 as cybersecurity-relevant general requirements; Art. 83–88 on post-market surveillance and vigilance.

Medical Device Coordination Group / Europäische Kommission · 2020

MDCG 2019-16 Rev. 1 – Guidance on Cybersecurity for medical devices

Central guidance on implementing the Annex I requirements: secure by design, security capabilities, joint responsibility, PMS/vigilance including IMDRF codes.

IEC · 2021

IEC 81001-5-1:2021 – Health software and health IT systems safety, effectiveness and security – Part 5-1: Security – Activities in the product life cycle

Process standard for the secure life cycle of health software (extension of IEC 62304, modelled on IEC 62443-4-1); EN version 2022, not yet harmonised in the Official Journal of the EU.

Medical Device Coordination Group / Europäische Kommission · 2025

MDCG 2025-6 – FAQ on Interplay between the Medical Devices Regulation & In vitro Diagnostic Medical Devices Regulation and the Artificial Intelligence Act

36 questions and answers on the interplay between the MDR/IVDR and the AI Act, including high-risk classification, roles and combined conformity assessment.

Amtsblatt der EU / EUR-Lex · 2024

Verordnung (EU) 2024/1689 (KI-Verordnung)

Art. 6(1) classifies AI-based medical devices requiring notified body involvement as high-risk AI; the application date for embedded high-risk AI was postponed to 2 August 2028 by the 2026 Digital Omnibus.

Team-NB (The European Association of Medical Devices Notified Bodies) · 2022

Team-NB Position Paper „Cyber Security“ V1

Joint position of the notified bodies on the conformity assessment of cybersecurity under the MDR/IVDR; complemented by a Team-NB letter of February 2026 on the harmonisation of standards.

Looking to demonstrate MDR cybersecurity in a structured way?

From a gap analysis against MDCG 2019-16 and IEC 81001-5-1 to audit-proof vulnerability handling: talk to us about a no-obligation initial consultation.